The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial
Open accessAbstract
In patients with type 1 diabetes, measurement of connecting peptide (C-peptide), cosecreted with insulin from the islets of Langerhans, permits estimation of remaining β-cell secretion of insulin. In this retrospective analysis to distinguish the incremental benefits of residual β-cell activity in type 1 diabetes, stimulated (90 min following ingestion of a mixed meal) C-peptide levels at entry in the Diabetes Control and Complications Trial (DCCT) were related to measures of diabetic retinopathy and nephropathy and to incidents of severe hypoglycemia. Based on the analytical sensitivity of the assay (0.03 nmol/l) and study entry criteria, the DCCT subjects were divided into four groups of stimulated C-peptide responses: ≤0.03, 0.04–0.20, 0.21–0.50 nmol/l at entry, and 0.21–0.50 nmol/l at entry and at least 1 year later (sustained C-peptide secretion). Uniformly in the intensive and partially in the conventional DCCT treatment groups, any C-peptide secretion, but especially at higher and sustained levels of stimulated C-peptide, was associated with reduced incidences of retinopathy (both a single three-step change and a repeated three-step change on the Early Treatment of Diabetic Retinopathy Study [ETDRS] scale at the next 6 month visit) and nephropathy (both albuminuria >40 mg/24 h once and repeated at the next annual visit). There were also differences in severe hypoglycemia across C-peptide levels in both treatment groups. In the intensively treated cohort there were essentially identical prevalences of severe hypoglycemia (∼65% of participants) in the first three groups; however, those subjects with mixed-meal stimulated C-peptide level >0.20 nmol/l for at least baseline and the first annual visit in the DCCT experienced a reduced prevalence of ∼30%. Therefore, even modest levels of β-cell activity at entry in the DCCT were associated with reduced incidences of retinopathy and nephropathy. Also, continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although this endogenous secretion is typically low, maintenance is important since it is associated with less retinopathy and less severe hypoglycaemia at later stages of the disease.86”
From Type 1 diabetes (2014) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“natural history studies, intervention trials, and transplantation studies consistently show that higher Cpeptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced longterm complications.[55][56][57]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This finding is noteworthy because in the Diabetes Control and Complications Trial68,69 persistent C-peptide secretion was associated with reduced development of retinopathy, nephropathy, and hypoglycaemia.”
From Type 1 diabetes (2018) · cites this paper as [69]
In the citing paper
“In addition, we analysed two other thresholds: UCPCR≥0.03 nmol/mmol and ≥0.2nmol/mmol, which are equivalent to serum C peptide of 30 pmol/L (a common historical limit of detection(3; 11; 12)) and 200 pmol/L (a clinically defined level associated with reduced microvascular complications and hypoglycaemia(13)).”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,602
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
The DCCT Research Group (1986) · Diabetes · doi:10.2337/diabetes.35.5.530 · Cited by 466
(1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100010038019 · Cited by 325
Hypoglycemia: The Limiting Factor in the Management of IDDM
Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.11.1378 · Cited by 307
THE DCCT RESEARCH GROUP (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-30 · Cited by 215
Flagged first, then by citations
Cited by
Sorted by citations
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J. P., Dralle, H., Ebeling, P. R., Melmed, S. K., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,500
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C., Hamilton, J. K., HAY, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,273
Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
A practical review of C-peptide testing in diabetes
Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0265-4 · Cited by 773
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725
The clinical utility of C‐peptide measurement in the care of patients with diabetes
Jones, A. G., & Hattersley, A. T. (2013) · Diabetic Medicine · doi:10.1111/dme.12159 · Cited by 666
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Voltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simões, B. P., et al. (2007) · JAMA · doi:10.1001/jama.297.14.1568 · Cited by 573
GAD treatment and insulin secretion in recent-onset type 1 diabetes
Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804328 · Cited by 520
Keenan, H. A., Sun, J. K., Levine, J., Doria, A., Aiello, L. P., Eisenbarth, G., Bonner-Weir, S., & King, G. L. (2010) · Diabetes · doi:10.2337/db10-0676 · Cited by 500
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Self-citationWhat are the health benefits of physical activity in type 1 diabetes mellitus? A literature review
Chimen, M., Kennedy, A., Nirantharakumar, K., Pang, T. T., Andrews, R., & Narendran, P. (2012) · Diabetologia · doi:10.1007/s00125-011-2403-2 · Cited by 438
Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371
Cardiac autonomic neuropathy in patients with diabetes mellitus
Dimitropoulos, G. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i1.17 · Cited by 364
Moran, A., Bundy, B. N., BECKER, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60023-9 · Cited by 364
Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes
Thompson, P. J., Shah, A., Ntranos, V., Van Gool, F., Atkinson, M., & Bhushan, A. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.021 · Cited by 353
Tersey, S. A., Nishiki, Y., Templin, A. T., Cabrera, S. M., Stull, N. D., Colvin, S. C., Evans-Molina, C., Rickus, J. L., Maier, B., & Mirmira, R. G. (2012) · Diabetes · doi:10.2337/db11-1293 · Cited by 353
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castaño, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.-J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107096 · Cited by 340
Fall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes · doi:10.2337/db11-1538 · Cited by 319
Preserved β-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells
Carlsson, P., Schwarcz, E., Korsgren, O., & Blanc, K. L. (2014) · Diabetes · doi:10.2337/db14-0656 · Cited by 325
Keymeulen, B., Walter, M., Mathieu, C., Kaufman, L., Gorus, F., Hilbrands, R., Vandemeulebroucke, E., de Velde, U. V., Crenier, L., Block, C. E. M. D., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1644-9 · Cited by 322
Buzzetti, R., Tuomi, T., Mauricio, D., Pietropaolo, M., Zhou, Z., Pozzilli, P., & Leslie, R. D. (2020) · Diabetes · doi:10.2337/dbi20-0017 · Cited by 305
Oram, R. A., Jones, A. G., Besser, R. E. J., Knight, B. A., Shields, B. M., Brown, R. J., Hattersley, A. T., & McDonald, T. J. (2014) · Diabetologia · doi:10.1007/s00125-013-3067-x · Cited by 298
Leptin revisited: its mechanism of action and potential for treating diabetes
Coppari, R., & Bjørbæk, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3757 · Cited by 308
Rigby, M. R., Harris, K. M., Pinckney, A., DiMeglio, L. A., Rendell, M., Felner, E. I., Dostou, J. M., Gitelman, S. E., Griffin, K., Tsalikian, E., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81722 · Cited by 297
B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
Pescovitz, M. D., Greenbaum, C. J., Bundy, B. N., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., Moran, A., Raskin, P., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0626 · Cited by 300
Lachin, J. M., McGee, P., Palmer, J. P., & for the DCCT/EDIC Research Group (2014) · Diabetes · doi:10.2337/db13-0881 · Cited by 283
Clinical Applications of Diabetes Antibody Testing
Bingley, P. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1365 · Cited by 278
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308743 · Cited by 273
Adult-onset autoimmune diabetes: current knowledge and implications for management
Buzzetti, R., Zampetti, S., & Maddaloni, E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.99 · Cited by 271
Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes
Davis, A. K., DuBose, S. N., Haller, M. J., Miller, K. M., DiMeglio, L. A., Bethin, K. E., Goland, R. S., Greenberg, E. M., Liljenquist, D. R., Ahmann, A. J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1952 · Cited by 261
Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
Hagopian, W., Ferry, R. J., Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Daifotis, A. G., Herold, K. C., et al. (2013) · Diabetes · doi:10.2337/db13-0236 · Cited by 247
Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control
Duca, L. M., Wang, B., Rewers, M., & Rewers, A. (2017) · Diabetes Care · doi:10.2337/dc17-0558 · Cited by 241
Abdul-Rasoul, M. M., Habib, H. B., & Al-Khouly, M. (2006) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2006.00155.x · Cited by 238
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice
Fujikawa, T., Chuang, J.-C., Sakata, I., Ramadori, G., & Coppari, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008025107 · Cited by 225
Guidelines on the use of extracorporeal photopheresis
Knobler, R., Berlin, G., Calzavara‐Pinton, P., Greinix, H., Jaksch, P., Laroche, L., Ludvigsson, J., Quaglino, P., Reinisch, W., Scarisbrick, J. J., et al. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12311 · Cited by 224
Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus
Rother, K. I., & Harlan, D. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci23235 · Cited by 221
Orban, T., Bundy, B. N., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0604 · Cited by 218
Rigby, M. R., DiMeglio, L. A., Rendell, M., Felner, E. I., Dostou, J. M., Gitelman, S. E., Patel, C. M., Griffin, K., Tsalikian, E., Gottlieb, P. A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70111-6 · Cited by 213
Early prediction of autoimmune (type 1) diabetes.
Regnell, S. E., & Lernmark, Å. (2017) · Diabetologia · doi:10.1007/s00125-017-4308-1 · Cited by 195
Wang, L., Lovejoy, N. F., & Faustman, D. L. (2012) · Diabetes Care · doi:10.2337/dc11-1236 · Cited by 192
Etiological Approach to Characterization of Diabetes Type
Dabelea, D., Pihoker, C., Talton, J. W., D’Agostino, R. B., Fujimoto, W. Y., KLINGENSMITH, G. J., Lawrence, J. M., Linder, B. L., Marcovina, S. M., Mayer‐Davis, E. J., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2324 · Cited by 190
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00019-x · Cited by 186
Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era
Akil, A. A., Yassin, E., Al-Maraghi, A., ALIYEV, E. E., Al-Malki, K., & Fakhro, K. A. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02778-6 · Cited by 217
Hypoglycemia: Still The Limiting Factor in the Glycemic Management of Diabetes
Cryer, P. E. (2008) · Endocrine Practice · doi:10.4158/ep.14.6.750 · Cited by 184
Insulin therapy and hypoglycemia
McCall, A. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.001 · Cited by 177
Forlenza, G. P., McVean, J., Beck, R. W., Bauza, C., Bailey, R., Buckingham, B., DiMeglio, L. A., Sherr, J. L., Clements, M., Neyman, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.2064 · Cited by 169
Natural History of β-Cell Function in Type 1 Diabetes
Sherry, N., Tsai, E. B., & Herold, K. C. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s32 · Cited by 172
Insulin Secretion in Type 1 Diabetes
Steele, C., Hagopian, W., Gitelman, S. E., Masharani, U. B., Cavaghan, M. K., Rother, K. I., DONALDSON, D. L., Harlan, D. M., Bluestone, J. A., & Herold, K. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.426 · Cited by 169
Faustman, D. L., Wang, L., Okubo, Y., Burger, D., Ban, L., Man, G., Zheng, H., Schoenfeld, D., Pompei, R. J., Avruch, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041756 · Cited by 168
Curative and β cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice
Koulmanda, M., Bhasin, M., Hoffman, L. K., Fan, Z., Qipo, A., Shi, H., Bonner‐Weir, S., Putheti, P., Degauque, N., Libermann, T. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808031105 · Cited by 165
Herold, K. C., Gitelman, S. E., Willi, S. M., Gottlieb, P. A., Waldron-Lynch, F., Devine, L., Sherr, J. L., Rosenthal, S. M., Adi, S., Jalaludin, M. Y., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2753-4 · Cited by 166
Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
Sosenko, J. M., Palmer, J. P., Greenbaum, C. J., Mahon, J. L., Cowie, C. C., Krischer, J. P., Chase, H. P., White, N. H., Buckingham, B. A., Herold, K. C., et al. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1006 · Cited by 157
Paris, C. A., Imperatore, G., KLINGENSMITH, G. J., Petitti, D. B., Rodríguez, B. L., Anderson, A., Schwartz, I. D., Standiford, D. A., & Pihoker, C. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.01.063 · Cited by 153
Hao, W., Gitelman, S., DiMeglio, L. A., Boulware, D. C., Greenbaum, C. J., & for the Type 1 Diabetes TrialNet Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0360 · Cited by 153
Järvelä, I. Y., Juutinen, J., Koskela, P. U., Hartikainen, A., Kulmala, P., Knip, M., & Tapanainen, J. S. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1118 · Cited by 147
Couper, J., Haller, M. J., Greenbaum, C. J., Ziegler, A., Wherrett, D. K., Knip, M., & Craig, M. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12734 · Cited by 153
Inhibition of GSK3 Promotes Replication and Survival of Pancreatic Beta Cells
Mußmann, R., Geese, M., Harder, F., Kegel, S., Andag, U., Lomow, A., Burk, U., Onichtchouk, D., Dohrmann, C. E., & Austen, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609637200 · Cited by 147
Gitelman, S. E., Gottlieb, P. A., Rigby, M. R., Felner, E. I., Willi, S. M., Fisher, L. K., Moran, A., Gottschalk, M. E., Moore, W. V., Pinckney, A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70065-2 · Cited by 143
Duca, L. M., Reboussin, B. A., Pihoker, C., Imperatore, G., Saydah, S., Mayer‐Davis, E. J., Rewers, A., & Dabelea, D. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12809 · Cited by 140
Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes
Keymeulen, B., Groot, K. D., Jacobs-Tulleneers-Thevissen, D., Thompson, D. M., Bellin, M., Kroon, E. J., Daniels, M., Wang, R. M., Jaiman, M. S., Kieffer, T., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-02055-5 · Cited by 117
Maddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14785 · Cited by 135
Oram, R. A., McDonald, T. J., Shields, B. M., Hudson, M. M., Shepherd, M. H., Hammersley, S., Pearson, E. R., Hattersley, A. T., & on behalf of the UNITED Team (2015) · Diabetes Care · doi:10.2337/dc14-0871 · Cited by 133
Panero, F., Novelli, G., Zucco, C., Fornengo, P., Perotto, M., Segre, O., Grassi, G., Cavallo‐Perin, P., & Bruno, G. (2008) · Diabetes Care · doi:10.2337/dc08-1241 · Cited by 132
Pitocco, D., Crinò, A., Stasio, E. D., Manfrini, S., Guglielmi, C., Spera, S., Anguissola, G. B., Visalli, N., SURACI, C., Matteoli, M. C., et al. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01921.x · Cited by 132
Extracorporeal Photopheresis—An Overview
Cho, A., Jantschitsch, C., & Knobler, R. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00236 · Cited by 136
Low levels of C‐peptide have clinical significance for established Type 1 diabetes
Kuhtreiber, W. M., Washer, S. L. L., Hsu, E., Zhao, M., Reinhold, P., Burger, D., Zheng, H., & Faustman, D. L. (2015) · Diabetic Medicine · doi:10.1111/dme.12850 · Cited by 131
Fiorina, P., Gremizzi, C., Maffi, P., Caldara, R., Tavano, D., Monti, L. D., Socci, C., Folli, F. B., Fazio, F., Astorri, E., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1358 · Cited by 130
Type 1 diabetes: A predictable disease
Simmons, K. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.380 · Cited by 129
Type 1 Diabetes TrialNet–An International Collaborative Clinical Trials Network
Skyler, J. S., Greenbaum, C. J., Lachin, J. M., Leschek, E., Rafkin‐Mervis, L., Savage, P. J., Spain, L. M., & the Type 1 Diabetes TrialNet Study Group (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.054 · Cited by 119
Jeyam, A., Colhoun, H., McGurnaghan, S., Blackbourn, L., McDonald, T. J., Palmer, C. N. A., McKnight, J. A., Strachan, M. W. J., Patrick, A. W., Chalmers, J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-0567 · Cited by 118
High residual C-peptide likely contributes to glycemic control in type 1 diabetes
Rickels, M. R., Evans‐Molina, C., Bahnson, H. T., Ylescupidez, A., Nadeau, K. J., Hao, W., Clements, M. A., Sherr, J. L., Pratley, R. E., Hannon, T. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134057 · Cited by 123
Age at Onset and the Risk of Proliferative Retinopathy in Type 1 Diabetes
Hletala, K., Harjutsalo, V., Forsblom, C. M., Summanen, P. A., Groop, P., & on behalf of the flnndlane study Group (2010) · Diabetes Care · doi:10.2337/dc09-2278 · Cited by 113
Lazar, L., Ofan, R., Weintrob, N., Avron, A., Tamir, M., Elias, D., Phillip, M., & JOSEFSBERG, Z. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.711 · Cited by 111
Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes
Boughton, C. K., Allen, J. M., Ware, J., Wilinska, M. E., Hartnell, S., Thankamony, A., Randell, T. L., Ghatak, A., Besser, R. E. J., Elleri, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203496 · Cited by 113
Subcutaneous insulin: pharmacokinetic variability and glycemic variability
Guerci, B., & Sauvanet, J.-P. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(05)88263-1 · Cited by 109
C-peptide: New findings and therapeutic possibilities
Wahren, J., & Larsson, C. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.016 · Cited by 108
High doses of dexamethasone induce increased β-cell proliferation in pancreatic rat islets
Rafacho, A., Cestari, T. M., Taboga, S. R., Boschero, A. C., & Bosqueiro, J. R. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90931.2008 · Cited by 110
Latent Autoimmune Diabetes in Adults: Current Status and New Horizons
Pozzilli, P., & Pieralice, S. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.2.147 · Cited by 111
Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management
Pieralice, S., & Pozzilli, P. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0190 · Cited by 109
Raz, I., Avron, A., Tamir, M., Metzger, M., Symer, L., Eldor, R., Cohen, I. R., & Elias, D. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.712 · Cited by 105
Racial/Ethnic Minority Youth With Recent-Onset Type 1 Diabetes Have Poor Prognostic Factors
REDONDO, M. J., Libman, I. M., Cheng, P., Kollman, C., Tosur, M., Gal, R. L., Bacha, F. F., KLINGENSMITH, G. J., Clements, M. A., REDONDO, M. J., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2335 · Cited by 104
Ren, J., Jin, P., Wang, E., Liu, E., Harlan, D. M., Li, X., & Stroncek, D. F. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-1 · Cited by 106
Too Much Glucagon, Too Little Insulin
Brown, R. J., Sinaii, N., & Rother, K. I. (2008) · Diabetes Care · doi:10.2337/dc08-0575 · Cited by 104
Standardization of C-peptide measurements
Little, R. R., Rohlfing, C. L., Tennill, A. L., Madsen, R. W., Polonsky, K. S., Myers, G. L., Greenbaum, C. J., Palmer, J. P., Rogatsky, E., & Stein, D. T. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.101287 · Cited by 103
Steck, A. K., Dong, F., Rasmussen, C. G., BAUTISTA, K. A., Sepulveda, F., Baxter, J., Yu, L., Frohnert, B. I., & Rewers, M. (2021) · Diabetes Care · doi:10.2337/dc21-0602 · Cited by 105
Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data
Brown, R. J., & Rother, K. I. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00272.x · Cited by 102
Interventions for latent autoimmune diabetes (LADA) in adults
Brophy, S. T., Davies, H. A., Mannan, S., Brunt, H., & Williams, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006165.pub3 · Cited by 105
β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy
Harrison, L., ADAMS-HUET, B. A., Raskin, P., & Lingvay, I. (2012) · Diabetes Care · doi:10.2337/dc11-2170 · Cited by 100
Preventing type 1 diabetes in childhood
Dayan, C. M., Besser, R. E. J., Oram, R. A., Hagopian, W., Vatish, M., Bendor-Samuel, O., Snape, M. D., & Todd, J. A. (2021) · Science · doi:10.1126/science.abi4742 · Cited by 102
Changing the landscape for type 1 diabetes: the first step to prevention
Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N., & Herold, K. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32127-0 · Cited by 96
Lin, G., Wang, G., Liu, G., Yang, L.-J., Chang, L., Lue, T. F., & Lin, C. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0010 · Cited by 96
Rajalakshmi, R., Amutha, A., Ranjani, H., Ali, M. K., Ranjit Unnikrishnan, I., Anjana, R. M., Narayan, K. M. V., & Mohan, V. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.12.008 · Cited by 95
Wherrett, D. K., Chiang, J. L., Delamater, A. M., DiMeglio, L. A., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lovell, D. J., Orchard, T. J., Ryan, C. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1429 · Cited by 96
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Waldron-Lynch, F., & Herold, K. C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3402 · Cited by 96
Metadata
- Authors
- Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W.
- Affiliations
- University of Minnesota (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-03-01
- Volume
- 26
- Issue
- 3
- Pages
- 832-836
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1988519907
- Cited by
- 695
- References
- 25
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 30 · 2023: 34 · 2022: 39 · 2021: 49 · 2020: 38 · 2019: 29 · 2018: 31 · 2017: 32 · 2016: 30 · 2015: 44 · 2014: 32 · 2013: 53 · 2012: 37
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (M01RR000400, M01-RR00400)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, residual beta-cell function, C-peptide, diabetic retinopathy, diabetic nephropathy, albuminuria, severe hypoglycemia, intensive insulin therapy, diabetes complications, Diabetes Control and Complications Trial
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Islets of Langerhans, Male, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
